Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Co., Ltd.
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO CO., LTD.

(4568)
  Report
Delayed Japan Exchange  -  02:00 2022-10-07 am EDT
4277.00 JPY   -0.37%
09/29DAIICHI SANKYO CO., LTD. : Ex-dividend day for interim dividend
FA
09/28Japan's Nikkei tracks Wall Street higher as Treasury yields fall
RE
09/22At U.N., Micronesia denounces Japan plan to release Fukushima water into Pacific
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Daiichi Sankyo Shares Gain After It Wins Dispute Over Cancer Drug Technology

08/14/2022 | 10:17pm EDT

By Kosaku Narioka


Daiichi Sankyo Co. shares rose sharply Monday morning after the Japanese drugmaker said an arbitrator ruled in its favor in a dispute over a cancer drug technology.

The stock was recently 14% higher at 4,200 yen ($31.47) after rising as much as 17% earlier.

Daiichi Sankyo said Saturday that an arbitrator issued a decision in a dispute between the company and Seagen Inc., denying all claims made by the American biotechnology company over an antibody-drug conjugate technology.

Daiichi Sankyo said Seagen had claimed certain intellectual property rights related to the antibody-drug conjugate technology and filed an arbitration demand with the American Arbitration Association in November 2019.

Roger Dansey, Seagen's interim Chief Executive Officer, said in a statement that while the arbitration decision was disappointing, it was important for the company to pursue the legal action. He added the ruling would not affect its existing business.

Jefferies analysts Naoya Miura and Stephen Barker said in a research note that they had provisionally assumed 5% of royalty payments for the possible settlement from net sales of Daiichi Sankyo's drugs using the technology from the mid-2022.

"This conclusion not only shows that Daiichi Sankyo was not obliged to pay any royalties, but also demonstrates Daiichi's strength of legal actions," the analysts said.


Write to Kosaku Narioka at kosaku.narioka@wsj.com


(END) Dow Jones Newswires

08-14-22 2216ET

Stocks mentioned in the article
ChangeLast1st jan.
DAIICHI SANKYO CO., LTD. -0.37% 4277 Delayed Quote.46.77%
MIURA CO., LTD. -2.54% 3065 Delayed Quote.-20.58%
SEAGEN INC. -3.68% 131.26 Delayed Quote.-11.85%
All news about DAIICHI SANKYO CO., LTD.
09/29DAIICHI SANKYO CO., LTD. : Ex-dividend day for interim dividend
FA
09/28Japan's Nikkei tracks Wall Street higher as Treasury yields fall
RE
09/22At U.N., Micronesia denounces Japan plan to release Fukushima water into Pacific
RE
09/22India's Fortis sinks 20% as top court extends stay on IHH open offer
RE
09/20Spectrum Pharmaceuticals' Cancer Drug Candidate Draws FDA Concerns About Safety, Benefi..
MT
09/20U.S. FDA staff raises concerns on Spectrum Pharma's cancer drug
RE
09/16Tepco to revise power prices for industry, factoring in nuclear restart
RE
09/11AstraZeneca's Enhertu Shrinks Tumor Size in Mid-stage Lung Cancer Study
MT
09/11ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with..
BU
09/10DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of ..
BU
More news
Analyst Recommendations on DAIICHI SANKYO CO., LTD.
More recommendations
Financials
Sales 2023 1 173 B 8 081 M 8 081 M
Net income 2023 92 072 M 634 M 634 M
Net cash 2023 660 B 4 548 M 4 548 M
P/E ratio 2023 89,6x
Yield 2023 0,64%
Capitalization 8 198 B 56 462 M 56 462 M
EV / Sales 2023 6,42x
EV / Sales 2024 5,56x
Nbr of Employees 16 458
Free-Float 97,8%
Chart DAIICHI SANKYO CO., LTD.
Duration : Period :
Daiichi Sankyo Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 4 277,00 JPY
Average target price 4 842,86 JPY
Spread / Average Target 13,2%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa General Manager-Administration
Noritaka Uji Chairman
Masahiko Ohtsuki Manager-Research & Development Planning
Wataru Takasaki General Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO CO., LTD.46.77%56 843
JOHNSON & JOHNSON-5.35%425 691
ELI LILLY AND COMPANY20.11%316 361
ROCHE HOLDING AG-14.13%271 357
ABBVIE INC.3.61%248 046
PFIZER, INC.-25.28%241 836